Feng Huang Wang Cai Jing·2026-02-13 14:49Group 1 - US stock indices opened lower, with Nasdaq down 0.16%, Dow Jones down 0.04%, and S&P 500 down 0.01% [1] - Chinese concept stocks fell, with Alibaba and Baidu dropping over 3%. However, Applied Materials rose over 11% due to better-than-expected Q1 earnings. Rivian surged 26% after projecting a 53% increase in delivery volume by 2026 [1] Group 2 - Eli Lilly's acquisition of Ventyx Biosciences has received approval from the US Federal Trade Commission, with a cash purchase price of $14 per share, totaling approximately $1.2 billion. The deal is expected to close in the first half of 2026 [2] Group 3 - Moderna reported Q4 revenue of $678 million, a 30% year-over-year decline, while the market had expected $625.1 million. The company posted a Q4 loss of $2.11 per share, an improvement from a loss of $2.91 per share in the same period last year [3] Group 4 - SoftBank's PayPay has officially submitted an IPO application in the US, reporting a profit of 103.3 billion yen and revenue of 278.5 billion yen for the nine months ending December 31 [4] Group 5 - TrendForce forecasts that HBM4 validation will be completed by Q2 2026, driven by growing GPU demand due to AI infrastructure expansion. Major memory manufacturers are nearing the end of the HBM4 validation process, with Samsung expected to lead, followed by SK Hynix and Micron [5]